Muscle Wasting Disorders Market Research Report By Disease Type (Muscular Dystrophy, Spinal Muscular Atrophy, Amyotrophic Lateral Sclerosis (ALS), Myasthenia Gravis, Other Muscle Wasting Disorders), By Treatment Modality (Drug Therapies, Gene Therapy, Physical Therapy and Rehabilitation, Supplements and Nutrition, Other Treatment Modalities), By Mechanism of Action (Anti-inflammatory Agents, Muscle Growth Stimulators, Gene Editing Therapies, Immunomodulators, Other Mechanisms of Action), By Route of Administration (Oral, Intravenous, Intram

Global Muscle Wasting Disorders Market Overview

As per MRFR analysis, the Muscle Wasting Disorders Market Size was estimated at 8.57 (USD Billion) in 2023. The Muscle Wasting Disorders Market Industry is expected to grow from 9.21 USD Billion) in 2024 to 16.5 (USD Billion) by 2032. The Muscle Wasting Disorders Market CAGR (growth rate) is expected to be around 7.56% during the forecast period (2024 - 2032).

Key Muscle Wasting Disorders Market Trends Highlighted

The muscle wasting disorders market is driven by the increasing prevalence of neuromuscular diseases, such as muscular dystrophy, amyotrophic lateral sclerosis (ALS), and sarcopenia. Additionally, the growing elderly population, which is more susceptible to muscle loss, is contributing to market growth. Furthermore, advancements in gene and stem cell therapies are expected to create lucrative opportunities for market players.
Key market trends include the development of novel therapeutics, such as gene therapies and muscle-specific drugs, which aim to address the underlying causes of muscle wasting disorders. Additionally, the increasing focus on personalized medicine and precision therapeutics is expected to drive market growth. Furthermore, the growing adoption of wearable and mobile health technologies for monitoring and managing muscle wasting disorders is creating new opportunities for market players.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Muscle Wasting Disorders Market Drivers

Aging Population

The aging population is a major growth driver of the Muscle Wasting Disorders Market Industry. With age, people become more likely to experience muscle loss and weakness that has been associated with a range of age-related deterioration of metabolic and physiological functions. The list of factors contributing to muscle loss includes reduced physical activity, hormonal changes, and metabolic alterations. Muscle loss results in a variety of health issues affecting the quality of life and life expectancy in older adults.

These include falls, fractures, and disability, among other issues; that is why there is a growing demand for medications and therapies assisting in the prevention or delay of muscle wasting disorders. The muscle wasting disorders market is likely to grow significantly in the next 10 years due to the aging population and the increasing rates of muscle wasting disorders.

Rising Prevalence of Chronic Diseases

Another major growth driver for the Muscle Wasting Disorders Market Industry would be the increasing incidence of chronic diseases. Cancer, heart disease, and diabetes, all of which are chronic diseases, can lead to muscle wastage. There are numerous causes for muscle wastage, such as inflammation, malnourishment, and low levels of activity. It is more difficult to manage chronic diseases than one would think, and there are several major complications that would ensue once it starts.

As a result, many are asking for ways to prevent muscle wasting disorders from spreading to patients who suffer from chronic diseases.

Technological Advancements

Along with other industries, technological advancements also affect the Muscle Wasting Disorders Market Industry growth. New treatments and technologies are created and invented, and the ones that are more effective in preventing and treating muscle wasting disorders are welcomed and used. These means include new drugs, devices, and therapies as well. The latter will also lead to the growth of demand for muscle wasting disorder treatments.

Muscle Wasting Disorders Market Segment Insights

Muscle Wasting Disorders Market Disease Type Insights

The Disease Type segment includes a number of muscle wasting conditions that are characterized by degenerative conditions with time and eventual weakness of muscle structure. Muscular dystrophy is the dominant segment owing to the increased types of disease, including Duchenne muscular dystrophy, Becker muscular dystrophy, and others. Spinal Muscular Atrophy is a genetic condition that leads to the loss of motor neurons in the spinal path, leading to delayed or systemic muscle weakness and loss. Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease, is a condition in which the motor neurons located in the groin and spinal cord get affected, resulting in muscle paralysis with time.

Myasthenia Gravis is an autoimmune condition that can cause serious muscle weakness due to the production of antibodies that prevent the transmission of signals or any form of communication between the nerves and the muscles of the body. Other Muscle Wasting Diseases are a heterogeneous group that includes body myositis, mitochondrial myopathies, and inflammatory myopathies. The Market of The Muscle Wasting Disorders Market is estimated to grow at a lucrative rate.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Muscle Wasting Disorders Market Treatment Modality Insights

The Treatment Modality segment of the Muscle Wasting Disorders Market is divided into Drug Therapies, Gene Therapy, Physical Therapy and Rehabilitation, Supplements and Nutrition and Other Treatment Modalities. Drug Therapies had the maximum market share in 2023 and it is likely to remain the same throughout the forecast period. The key factors promoting this segment’s growth are the growing prevalence of muscle wasting disorders and the availability of a wide range of FDA-approved drugs for the treatment of these disorders. Gene Therapy is also an interesting segment with many ongoing clinical trials to evaluate the efficiency and safety of gene therapies for treating muscle wasting disorders.

Physical therapy and rehabilitation have an important role to play in treating muscular wasting diseases, and thus, they are expected to experience tremendous growth in the forecast period. Supplements and nutrition are increasingly being used as adjunct therapies for the treatment of these diseases. The remaining segment, Other Treatment Modalities, includes therapy using stem cells and electrical stimulation. Though in the nascent stages, they show future growth potential in terms of better efficiency and safety. The Muscle Wasting Disorders Market revenue is expected to rise to USD 10.23 billion by 2024, exhibiting a CAGR of 8.5% over the period.

Muscle Wasting Disorders Market Mechanism of Action Insights

The Muscle Wasting Disorders Market segmentation by Mechanism of Action includes Anti-inflammatory Agents, Muscle Growth Stimulators, Gene Editing Therapies, Immunomodulators, and Other Mechanisms of Action. Anti-inflammatory Agents held the largest market share of 35.2% in 2023 and is expected to continue its dominance throughout the forecast period. The growing prevalence of inflammatory muscle wasting disorders and the availability of effective anti-inflammatory drugs are driving the growth of this segment. Muscle Growth Stimulators are expected to witness the fastest growth during the forecast period, owing to the increasing adoption of these therapies for the treatment of muscle wasting disorders.

Gene Editing Therapies, Immunomodulators, and Other Mechanisms of Action are also expected to contribute to the growth of the Muscle Wasting Disorders Market during the forecast period.

Muscle Wasting Disorders Market Route of Administration Insights

The Muscle Wasting Disorders Market is segmented by Route of Administration into Oral, Intravenous, Intramuscular, Transdermal, and Other Routes of Administration. The Oral segment held the largest market share in 2023, accounting for over 50% of the market. The Intravenous segment is expected to witness the highest CAGR during the forecast period, owing to the increasing adoption of injectable therapies for muscle wasting disorders. The Transdermal segment is also expected to experience significant growth, driven by the development of novel transdermal drug delivery systems.

Other Routes of Administration, such as subcutaneous and rectal administration, are also expected to contribute to the market growth.

Muscle Wasting Disorders Market Regional Insights

The regional segmentation of the Muscle Wasting Disorders Market offers insights into the market's performance across different geographic regions. North America is expected to dominate the market, capturing a significant share due to the high prevalence of muscle wasting disorders and advanced healthcare infrastructure. Europe is projected to follow, driven by factors such as an increasing geriatric population and rising awareness about muscle wasting disorders. The Asia-Pacific region is anticipated to witness substantial growth, owing to the increasing healthcare expenditure and growing awareness about these disorders.

South America and the Middle East and Africa (MEA) regions are expected to contribute to the market growth, albeit at a slower pace, as they are characterized by limited healthcare infrastructure and lower awareness levels.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Muscle Wasting Disorders Market Key Players And Competitive Insights

Many of the top players in the Muscle Wasting Disorders Market industry are seeking to maintain their competitive advantage. Their strategies include extensive investments in research and development to expand their drug portfolios and enter into partnerships. Many muscle wasting treatment providers also attempt to develop new therapies and procedures to assist patients with a variety of illnesses. The field is anticipated to remain fragmented, with few companies maintaining a large proportion of the market. However, due to their reasonable and better pricing, therapy may become increasingly common in the coming years. Notably, again, the market’s leading players participate in associations. For example, in 2023, Sarepta Therapeutics announced that it would collaborate with Roche Pharmaceuticals to develop and sell gene therapies for muscle wasting diseases.

The association allows the firms to use one another’s assets, talents, and distribution networks to expedite the introduction of recovery programs to the market. Furthermore, the Muscle Wasting Disorders Market industry also has a growing number of acquisitions and mergers. As an example, PTC Therapeutics is a significant player in the market in question. It is dedicated to the development and commercialization of medications for rare illnesses. This business’s primary product, Translarna, is approved for use in patients with DMD, a type of muscular dystrophy that is prevalent in the US, Europe and the rest of the world. The company is also developing a number of therapies and programs for DMD sufferers and people with other kinds of muscle-wasting diseases. Also, PTC Therapeutics has a number of medicines for the early developmental and clinical phases. It is committed to the development of new medications and plans to embark on further R&D activities to address diseases that cannot now be treated.

Key Companies in the Muscle Wasting Disorders Market Include

• 
  

  C4 Therapeutics, Inc.

  
  


• 
  

  Biogen Inc.

  
  


• 
  

  Acceleron Pharma Inc.

  
  


• 
  

  Sanofi SA.

  
  


• 
  

  Dyno Therapeutics

  
  


• 
  

  ReveraGen Biopharma, Inc.

  
  


• 
  

  Celgene Corporation

  
  


• 
  

  Ultragenyx Pharmaceutical Inc.

  
  


• 
  

  Fulcrum Therapeutics

  
  


• 
  

  Ionis Pharmaceuticals, Inc.

  
  


• 
  

  EMA Therapeutics, Inc.

  
  


• 
  

  Horizon Therapeutics plc

  
  


• 
  

  PTC Therapeutics, Inc.

  
  


• 
  

  Novartis AG

  
  


• 
  

  Pfizer Inc.

  
  


• 
  

  F. HoffmannLa Roche Ltd.

  
  

Muscle Wasting Disorders Market Industry Developments

The Muscle Wasting Disorders market is expected to grow from USD 8.57 billion in 2023 to USD 16.5 billion by 2032, at a CAGR of 7.56%. Key factors driving the market growth include the increasing prevalence of muscle wasting disorders, rising demand for effective treatments, and growing awareness about these conditions.

Recent news developments in the market include:

In March 2023, PTC Therapeutics announced positive results from a Phase II clinical trial of its investigational drug, PTC596, for the treatment of Duchenne muscular dystrophy.
In April 2023, Sarepta Therapeutics received FDA approval for Amondys 45 (casimersen), a gene therapy for the treatment of Duchenne muscular dystrophy.

These developments indicate a promising future for the Muscle Wasting Disorders market, with continued innovation and research leading to new and improved treatments for patients.

Muscle Wasting Disorders Market Segmentation

Muscle Wasting Disorders Disease Type Outlook

1. 
   
   
   
   1. 
      

      Muscular Dystrophy

      
      
   
   
   2. 
      

      Spinal Muscular Atrophy

      
      
   
   
   3. 
      

      Amyotrophic Lateral Sclerosis (ALS)

      
      
   
   
   4. 
      

      Myasthenia Gravis

      
      
   
   
   5. 
      

      Other Muscle Wasting Disorders

      
      
   
   
   
   

Muscle Wasting Disorders Treatment Modality Outlook

                   Drug Therapies

                   Gene Therapy

2. 
   
   
   
   1. 
      

      Physical Therapy and Rehabilitation

      
      
   
   
   2. 
      

      Supplements and Nutrition

      
      
   
   
   3. 
      

      Other Treatment Modalities

      
      
   
   
   
   

Muscle Wasting Disorders  Mechanism of Action Outlook

1. 
   
   
   
   1. 
      

      Anti-inflammatory Agents

      
      
   
   
   2. 
      

      Muscle Growth Stimulators

      
      
   
   
   3. 
      

      Gene Editing Therapies

      
      
   
   
   4. 
      

      Immunomodulators

      
      
   
   
   5. 
      

      Other Mechanisms of Action

      
      
   
   
   
   

Muscle Wasting Disorders Route of Administration Outlook

1. 
   
   
   
   1. 
      

      Oral

      
      
   
   
   2. 
      

      Intravenous

      
      
   
   
   3. 
      

      Intramuscular

      
      
   
   
   4. 
      

      Transdermal

      
      
   
   
   5. 
      

      Other Routes of Administration

      
      
   
   
   
   

Muscle Wasting Disorders Regional Outlook

1. 
   
   
   
   1. 
      

      North America

      
      
   
   
   2. 
      

      Europe

      
      
   
   
   3. 
      

      South America

      
      
   
   
   4. 
      

      Asia Pacific

      
      
   
   
   5. 
      

      Middle East and Africa